Click the name of a recruiting city below to register for the study!

   CHICAGO   

 

   INDANAPOLIS   

 

   SEATTLE   

 

 

Study News
The study has launched,and recruitment is underway! Screening began in June 2013. The study is ongoing until 2018.

May 22, 2013
NIH published its offical news release for the launch of the RISE Study.

For More Information

View the map for participating clinics.  More information can be found on ClinicalTrials.gov (AdultPediatricBetaFat). 

 

About the RISE Studies

                     

 

  RISE includes 3 studies examining whether aggressive glucose lowering will lead to recovery of pancreas function (known as ß-cell function) in those with prediabetes and early type 2 diabetes.
   
 

1) RISE Adult Medication Study:

  • A 4-arm clinical trial in adults with prediabetes and early type 2 diabetes. 
  • Adult participants (ages 20-65) are randomized to one of the following treatment arms:
    • (1) metformin alone,
    • (2) insulin glargine followed by metformin,
    • (3) liraglutide plus metformin, or
    • (4) placebo.
  • The study is a collaboration among the VA Puget Sound Health Care System/University of WashingtonIndiana University, and the University of Chicago.
   
 

2) RISE Pediatric Medication Study:

  • A 2-arm clinical trial in children with prediabetes and early type 2 diabetes. 
  • Pediatric participants (ages 10-19) are randomized to either:
    • (1) insulin glargine followed by metformin or
    • (2) metformin-alone.
  • The study is a collaboration between the University of Colorado, Yale University, the University of Pittsburgh, and Indiana University.
   
 

3) Adult Surgery Study (BetaFat)

  • A 2-arm clinical trial in adults with prediabetes and early, drug-naive, type 2 diabetes. 
  • Adult participants (ages 22-65) are randomized to gastric banding or metformin.  
  • This study is taking place at The University of Southern California Keck School of Medicine.
   
 

PRIMARY QUESTIONS:

  • Are improvements in pancreas function following 12 months of each of the treatments maintained for 3 months following the withdrawal of therapy?
  • All 3 studies will also assess glucose tolerance after treatment, and whether other biomarkers predict pancreatic function, insulin sensitivity and glucose tolerance. 

 

 

Contact Information
Contact information for each clinic is listed under Participating Centers. To contact the RISE Coordinating Center, please click here.

 

Press Releases
NIH news release on RISE Study (05/22/2013)

 

Technical Support
Please contact the RISE webmaster with any problems with login or accessing documents from the website.